Method Specific

Intrauterine Contraception

FSRH Clinical Guideline: Intrauterine Contraception (April 2015, amended September 2019)

26 September 2019

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of intrauterine contraception (IUC) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK. This guideline was updated in September 2019.

This document is up-to-date

FSRH CEU statement Levosert 6 year license for contraception - Feb 2021

08 February 2021

This statement notes that the Levosert® 52mg LNG-IUS has been licensed for contraceptive use for 6 years. Levosert remains licensed for 5 years for management of heavy menstrual bleeding and is not licensed for endometrial protection as part of HRT.

This document is up-to-date

FSRH New Product Review: Intrauterine Ball (IUB™) SCu300B MIDI (February 2019)

11 February 2019

Manufactured by OCON Medical Ltd, the Intrauterine Ball (IUB™) SCu300B MIDI is a copper intrauterine device (Cu-IUD) comprised of copper beads with a total exposed copper surface of 300mm² strung on a flexible Nitinol (nickel/titanium alloy), PET-coated frame. Once the IUB is released from the 3.2mm diameter insertion tube into the uterus it coils into a spherical shape measuring 15mm in diameter. Download the product review in full here.

This document is up-to-date

Progestogen-only Implants

FSRH Clinical Guideline: Progestogen-only Implant (February 2021)

16 February 2021

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only implants currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

This document is up-to-date

FSRH CEU Statement on Nexplanon® Insertion Site 15 January 2020

15 January 2020

This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.

This document is up-to-date

FSRH CEU Guidance: Progestogen-only Implant Quick Reference Summary (February 2021)

16 February 2021

This summary has been written as a quick reference guide to help busy clinicians to give clear, safe advice on Progestogen-only Implant). Please refer to the full 2018 FSRH Progestogen-only Implant Clinical Guideline for further information and evidence for this advice. This document is written for FSRH members and requires you to log in to access it.

This document is up-to-date

Progestogen-only Injectables

FSRH Clinical Guideline: Progestogen-only Injectable (December 2014, Amended October 2020)

24 October 2020

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only injectables (depot medroxyprogesterone acetate (DMPA), Depo-Provera) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

This document is up-to-date

FSRH New Product Review: Sayana Press® (June 2013)

01 June 2013

Injectable progestogen-only contraception is a popular and effective method of contraception and until now, in the UK has largely been administered as Depo-Provera®, an intramuscular (IM) injection of 150mg medroxyprogesterone acetate (DMPA).

This document is up-to-date

Progestogen-only Pills

FSRH Clinical Guideline: Progestogen-only Pills (March 2015, Amended April 2019)

30 April 2019

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only pills currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

This document is up-to-date

Combined Hormonal Contraception

FSRH Clinical Guideline: Combined Hormonal Contraception (January 2019, Amended November 2020)

01 November 2020

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of combined hormonal contraceptives (i.e. the combined oral contraceptive pill, transdermal patch and combined vaginal ring) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

This document is up-to-date

FSRH CEU Guidance: Combined Hormonal Contraception Quick Reference Summary (January 2019, amended November 2020)

01 November 2020

This summary has been written as a quick reference guide to help busy clinicians to give clear, safe advice on combined hormonal contraception (CHC). Please refer to the full 2018 FSRH CHC Clinical Guideline for further information and evidence for this advice. This document is written for FSRH members and requires you to log in to access it.

This document is up-to-date

FSRH CEU Guidance: Recommended Actions after incorrect Use of Combined Hormonal Contraception (e.g. late or missed pills, ring and patch) (March 2020, amended July 2021)

16 March 2020

This document provides guidance on incorrect use of: combined oral contraceptive pills, the combined vaginal ring, and the combined transdermal patch. This guidance was developed with an international team of SRH experts. The panel used the limited relevant published evidence relating to risk of pregnancy associated with incorrect use of the combined pill, patch and ring to inform a set of rules that are overcautious, but are considered to be simple enough to make them usable in practice. The guidance was peer reviewed and went out to public consultation prior to final publication. The guidance is intended for use by health professionals working in SRH, general practice and obstetric and gynaecology settings, and can also be used by women using CHC. Download the document here.

This document is up-to-date

FSRH CEU Statement: Strengthening of Warnings about use of Dianette and other brands of co-cyprindiol (June 2013)

01 June 2013

Following a recent safety review, a letter has been issued to healthcare professionals from the manufacturers of Dianette® and other cyproterone acetate 2 mg/ ethinylestradiol 35 mcg (co-cyprindiol) products. The review by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) followed concerns about the risk of thrombosis associated with co-cyprindiol. With the agreement of the EMA and Medicines and Healthcare products Regulatory Authority (MHRA), a letter has been issued to raise awareness of the thrombosis risks and the outcome of the review.

This document is up-to-date

FSRH New Product Review: Eloine Daylette (November 2015)

01 November 2015

How effective is 20mcgEE/3mgDRSP as contraception? 20mcgEE/3mg DRSP is of comparable effectiveness to other combined oral contraceptives. [1,2,3] A large US observational study reports lower failure rates amongst users of a 24/4 EE/DRSP regimen than a 21/7 EE/DRSP regimen. The study also suggests greater contraceptive effectiveness of a 24/4 EE/DRSP regimen than with a 24/4 regimen containing EE in combination with norethisterone.

This document is up-to-date

FSRH New Product Review: Estradiol/Nomegestrol Combined Pill, Zoely© (May 2013)

01 May 2013

The combined oral contraceptive Zoely® (Merck, Sharp, and Dohme Limited) has been licensed in Europe since 2011 and will be available in the UK from May 2013. Zoely will be the second UK combined oral contraceptive (COC) to contain estradiol and to be formulated as an extended regimen since the introduction of Qlaira® (Bayer plc.)

This document is up-to-date

Barrier Methods

FSRH Clinical Guideline: Barrier Methods for Contraception and STI Prevention (August 2012, amended October 2015)

01 October 2015

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of barrier methods for contraception and STI prevention. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

Please read this guidance document in conjunction with any relevant clinical statements for this topic.

FSRH New Product Review: One size contraceptive diaphragm (Caya®) (August 2014)

01 August 2014

Diaphragms are non-hormonal barrier methods of contraception that protect women against pregnancy by preventing sperm reaching the cervix. A single size contraceptive cap, FemCap, has been available since 2004, but until recently diaphragm products have been made in a range of sizes and designs. As a result women may have been required to try several types of diaphragm during the fitting process.

This document is up-to-date

Male and Female Sterilisation

FSRH Clinical Guideline: Male and Female Sterilisation (September 2014)

01 September 2014

This guidance provides evidence-based recommendations and good practice points for health professionals on elective male sterilisation (vasectomy) and female sterilisation (tubal occlusion) in the UK. It is intended for any health care professional or service that undertakes or refers individuals for either procedure. This guidance has been jointly developed with the Royal College of Obstetricians and Gynaecologists (RCOG).

Please read this guidance document in conjunction with any relevant clinical statements for this topic.

FSRH CEU Statement: Response to the BMJ paper by Mao et. al. (October 2015)

01 October 2015

A large observational study from the United States found that the risk of unintended pregnancy after Essure sterilisation was similar to that after surgical sterilisation. However just over 2% of women who had Essure sterilisation required a further operation related to the sterilisation procedure within a year.

This document is up-to-date

Fertility Awareness Methods

FSRH Clinical Guideline: Fertility Awareness Methods (June 2015)

01 June 2015

This is a new guidance document that provides evidence-based recommendations and good practice points on the use of fertility awareness methods (FAM) for the purpose of preventing and/or spacing pregnancies. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

Please read this guidance document in conjunction with any relevant clinical statements for this topic.

Other